Innovative Medicine
-
U.S. FDA Approves INVEGA TRINZA™, First and Only Four-Times-A-Year Treatment for Schizophrenia
93% of patients treated with INVEGA TRINZA™ remained relapse-free at the end of long-term maintenance trial -
-
Janssen Highlights Hepatitis C Virus Development Program at The International Liver Congress™ 2015 of the European Association for the Study of the Liver (EASL)
Presentations include late-breaking final results from the Phase 3 OPTIMIST trials and interim results from the Phase 2 IMPACT trial of simeprevir -
Janssen Sets A Course To Intercept Type 1 Diabetes Together With JDRF
Unique Approach Aims to Intercept Disease Prior to Onset and Preserve Health of People At-risk of Developing Type 1 Diabetes -
PREZCOBIX™ (darunavir/cobicistat) Approved in the U.S. for the Treatment of Adults Living With HIV-1
Combined Fixed-Dose Tablet of Darunavir and Cobicistat Can Help Reduce Number of Pills in a Combination Antiretroviral Treatment Regimen -
U.S. FDA Approves IMBRUVICA® (ibrutinib) for the Treatment of Waldenström’s Macroglobulinemia: First FDA-Approved Therapy for This Disease
Approval represents fourth indication for IMBRUVICA in the U.S. -
-
Johnson & Johnson Announces Formation of Ebola Vaccine Development Consortia, Gains Funding from Innovative Medicines Initiative
Consortia funded through the IMI Ebola+ Programme Supported by the European Commission Brings together London School of Hygiene and Tropical Medicine, Inserm, University of Oxford, Le Centre Muraz, Bavarian Nordic A/S, Vibalogics, the Grameen Foundation and World Vision of Ireland with Janssen Pharmaceutical Companies to help accelerate Ad26 – MVA Ebola vaccine development and patient education -
Real-World Data Published in Clinical Cardiology Show Consistent Safety Performance of Once-Daily XARELTO®
Findings Add to Rigorous Post-Marketing Safety Program for XARELTO® in Routine Clinical Practice
